作者:Patrick R. Angibaud、Marc G. Venet、Walter Filliers、Rudy Broeckx、Yannick A. Ligny、Philippe Muller、Virginie S. Poncelet、Dave W. End
DOI:10.1002/ejoc.200300538
日期:2004.2
an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRATM) is currently undergoing clinical evaluation and recent studies have confirmed
Ras 癌蛋白的翻译后法呢基化是发挥其生物学效应的重要步骤,这一发现导致了法呢基蛋白转移酶抑制剂 (FTI) 的设计,以控制带有 Ras 突变的肿瘤的生长。对小鼠模型的临床前研究证实了它们对肿瘤生长的抑制作用并促进了临床开发。R115777 (ZARNESTRATM) 目前正在进行临床评估,最近的研究证实了其抗肿瘤潜力和低毒性。我们希望在此描述我们团队开发的用于访问 ZARNESTRATM 的化学合成路线。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004)